What does DR. WENDY DE ROOCK, medische oncologie do?

DR. WENDY DE ROOCK, medische oncologie is a specialist medical practice in Maasmechelen. Private Limited, started on 18 August 2012, 2 establishments.

What is the address of DR. WENDY DE ROOCK, medische oncologie?

The registered office of DR. WENDY DE ROOCK, medische oncologie is located at Marie Joséestraat(E) 15, 3630 Maasmechelen.

Is DR. WENDY DE ROOCK, medische oncologie still active?

Yes. According to the CBE (30 September 2026) DR. WENDY DE ROOCK, medische oncologie is active, legal situation “Normale toestand”, started on 18 August 2012.

Is DR. WENDY DE ROOCK, medische oncologie registered on Peppol?

Yes, DR. WENDY DE ROOCK, medische oncologie is registered on the Peppol network with ID 0208:0848223527.

What is the enterprise number of DR. WENDY DE ROOCK, medische oncologie?

The enterprise number of DR. WENDY DE ROOCK, medische oncologie is BE0848223527.

When was DR. WENDY DE ROOCK, medische oncologie founded?

DR. WENDY DE ROOCK, medische oncologie was founded on 18 August 2012.

Who are the directors of DR. WENDY DE ROOCK, medische oncologie?

According to the 2025 annual accounts, the directors of DR. WENDY DE ROOCK, medische oncologie are: WENDY DE ROOCK.

Is DR. WENDY DE ROOCK, medische oncologie a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 18 August 2012; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account; 2 establishments in the CBE.

How much profit did DR. WENDY DE ROOCK, medische oncologie make in 2025?

DR. WENDY DE ROOCK, medische oncologie posted a profit after taxes of € 233,429 in financial year 2025.

What is the revenue of DR. WENDY DE ROOCK, medische oncologie?

As a small company, DR. WENDY DE ROOCK, medische oncologie is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 320,728.

DR. WENDY DE ROOCK, medische oncologie (Private Limited)

Dossier DR. WENDY DE ROOCK, medische oncologie, printed on 30 September 2026 from databakkes.be/en/0848223527/dr-wendy-de-roock-medische-oncologie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

DR. WENDY DE ROOCK, medische oncologie from Maasmechelen, company number BE0848223527, closed financial year 2025 with a result of € 233,429 after tax. For that financial year DR. WENDY DE ROOCK, medische oncologie recorded a gross margin of € 320,728 and equity of € 930,338. Compared with financial year 2024, the result moved from € 273,389 to € 233,429. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 21, 2026.

What it is worth Healthy

€ 930,338

▼ 25% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 233,429

▼ 15% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 356,939

▲ 83% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 539,865 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Vehicles and equipment

€ 1,647

▼ 54% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 2,203

▼ 3% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 15,723

▲ 80% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 270,669 Gross margin 2022: € 270,669 First fiscal year in the series	€ 316,659 Gross margin 2023: € 316,659 ▲ 17% vs 2022 (€ 270,669) Favourable step	€ 318,648 Gross margin 2024: € 318,648 ▲ 1% vs 2023 (€ 316,659) Favourable step	€ 320,728 Gross margin 2025: € 320,728 ▲ 1% vs 2024 (€ 318,648) Favourable step	▲ 1%
Profit after taxes	€ 188,431 Profit after taxes 2022: € 188,431 First fiscal year in the series	€ 220,828 Profit after taxes 2023: € 220,828 ▲ 17% vs 2022 (€ 188,431) Favourable step	€ 273,389 Profit after taxes 2024: € 273,389 ▲ 24% vs 2023 (€ 220,828) Favourable step	€ 233,429 Profit after taxes 2025: € 233,429 ▼ 15% vs 2024 (€ 273,389) Unfavourable step	▼ 15%
Equity	€ 1,030,639 Equity 2022: € 1,030,639 First fiscal year in the series	€ 1,117,932 Equity 2023: € 1,117,932 ▲ 8% vs 2022 (€ 1,030,639) Favourable step	€ 1,236,774 Equity 2024: € 1,236,774 ▲ 11% vs 2023 (€ 1,117,932) Favourable step	€ 930,338 Equity 2025: € 930,338 ▼ 25% vs 2024 (€ 1,236,774) Unfavourable step	▼ 25%
Total debts	€ 30,652 Total debts 2022: € 30,652 First fiscal year in the series	€ 29,883 Total debts 2023: € 29,883 ▼ 3% vs 2022 (€ 30,652) Favourable step	€ 11,005 Total debts 2024: € 11,005 ▼ 63% vs 2023 (€ 29,883) Favourable step	€ 346,042 Total debts 2025: € 346,042 ▲ € 335,037 vs 2024 (€ 11,005) Unfavourable step	▲ € 335,037
Cash	€ 411,626 Cash 2022: € 411,626 First fiscal year in the series	€ 360,995 Cash 2023: € 360,995 ▼ 12% vs 2022 (€ 411,626) Unfavourable step	€ 194,991 Cash 2024: € 194,991 ▼ 46% vs 2023 (€ 360,995) Unfavourable step	€ 356,939 Cash 2025: € 356,939 ▲ 83% vs 2024 (€ 194,991) Favourable step	▲ 83%
Retained profit	€ 1,016,379 Retained profit 2022: € 1,016,379 First fiscal year in the series	€ 1,103,672 Retained profit 2023: € 1,103,672 ▲ 9% vs 2022 (€ 1,016,379) Favourable step	€ 1,222,514 Retained profit 2024: € 1,222,514 ▲ 11% vs 2023 (€ 1,103,672) Favourable step	€ 916,078 Retained profit 2025: € 916,078 ▼ 25% vs 2024 (€ 1,222,514) Unfavourable step	▼ 25%
Dividend	€ 154,301 Dividend 2022: € 154,301 First fiscal year in the series	€ 133,536 Dividend 2023: € 133,536 ▼ 13% vs 2022 (€ 154,301) Unchanged	€ 154,548 Dividend 2024: € 154,548 ▲ 16% vs 2023 (€ 133,536) Unchanged	€ 539,865 Dividend 2025: € 539,865 ▲ 249% vs 2024 (€ 154,548) Unchanged	▲ 249%
Balance sheet total	€ 1,061,291 Balance sheet total 2022: € 1,061,291 First fiscal year in the series	€ 1,147,815 Balance sheet total 2023: € 1,147,815 ▲ 8% vs 2022 (€ 1,061,291) Unchanged	€ 1,247,779 Balance sheet total 2024: € 1,247,779 ▲ 9% vs 2023 (€ 1,147,815) Unchanged	€ 1,276,380 Balance sheet total 2025: € 1,276,380 ▲ 2% vs 2024 (€ 1,247,779) Unchanged	▲ 2%

Key figures of DR. WENDY DE ROOCK, medische oncologie, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to DR. WENDY DE ROOCK, medische oncologie?

What happened at DR. WENDY DE ROOCK, medische oncologie in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 21, 2026 New annual accounts for financial year 2025: profit of € 233,429 (▼ 15% vs 2024). filed late Source: NBB ↗
Oct 13, 2024 New establishment in Genk. KBO
Aug 24, 2012 New establishment in Maasmechelen. KBO
Aug 18, 2012 Start of the company according to the CBE. KBO

In short

From € 188,431 profit in 2022 to € 233,429 profit in 2025.

Paid € 384,680 in corporate taxes since 2022.

Best year ever: 2024, with € 273,389 profit.

Paid out € 982,249 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at DR. WENDY DE ROOCK, medische oncologie? We notify you, reason included.

Follow DR. WENDY DE ROOCK, medische oncologie

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

WENDY DE ROOCK

DR. WENDY DE ROOCK, medische oncologie

Behind DR. WENDY DE ROOCK, medische oncologie is WENDY DE ROOCK.

See the full network in the app

Directors

According to the 2025 annual accounts

WENDY DE ROOCK

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Marie Joséestraat(E) 15

3630 Maasmechelen

2.364.868.512

Synaps Park 1

3600 Genk

Active since 13 October 2024

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0848.223.527
VAT number: BE 0848.223.527
Registered office: Marie Joséestraat(E) 15, 3630 Maasmechelen
Names & denominations: DR. WENDY DE ROOCK, medische oncologie
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 18 August 2012
Peppol: Active · Active since 27 Mar 2026
Activities · NACE: Activiteiten van medisch specialisten

View on CBE Public ↗ Annual accounts (NBB) ↗